<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849030</url>
  </required_header>
  <id_info>
    <org_study_id>1033IL/0029</org_study_id>
    <secondary_id>D5392C00029</secondary_id>
    <nct_id>NCT00849030</nct_id>
  </id_info>
  <brief_title>ATAC - Arimidex, Tamoxifen Alone or in Combination</brief_title>
  <official_title>A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is
      beneficial in the treatment of breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence of breast cancer</measure>
    <time_frame>Earliest of local or distant recurrence, new primary breast cancer, or death</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and side effects</measure>
    <time_frame>Earliest of local or distant recurrence, new primary breast cancer, or death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to distant recurrence</measure>
    <time_frame>Earliest of local or distant recurrence, new primary breast cancer, or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Earliest of local or distant recurrence, new primary breast cancer, or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New breast primaries</measure>
    <time_frame>Earliest of local or distant recurrence, new primary breast cancer, or death</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9358</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arimidex 1mg + Nolvadex placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arimidex placebo + Nolvadex 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arimidex 1mg + Nolvadex 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastozole (Arimidex)</intervention_name>
    <description>1mg, orally, once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen (Nolvadex)</intervention_name>
    <description>20mg, orally, once daily</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastozole (Arimidex) placebo</intervention_name>
    <description>1mg, orally, once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen (Nolvadex) placebo</intervention_name>
    <description>20mg, orally, once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven operable invasive breast cancer

          -  Patients who have completed all primary surgery and chemotherapy (if given), and are
             candidates to receive hormonal adjuvant therapy

          -  Women defined as post-menopausal

        Exclusion Criteria:

          -  Patients in whom there is any clinical evidence of metastatic disease

          -  Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are
             unlikely to comply with trial requirements

          -  Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after
             completion of primary surgery or whose chemotherapy was completed more than 8 weeks
             (ie 56 days) before starting randomised treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

